Tg(Ckm-Prkaa2*D157A)1Ljg

The transgenic construct contains a rat cDNA containing the Prkaa2 gene modified by site-directed mutagenesis to contain the D157A mutation under the control of the muscle creatine kinase promoter. The mutation changes the aspartic acid at residue 157 to alanine thus inactivating the catalytic alpha 2 subunit. The inactive alpha 2 subunit is tagged with a hemaglutinin epitope at the amino terminus. Expression of endogenous Prkaa2 is detectable only after very long exposure times and transgene expression occurs in skeletal muscle. (J:104111)